Skip to main content
SpringerLink
Log in

Screening and Prevention of Carcinoma Endometrium

  • Chapter
Uterine Cancer

  • 1184 Accesses

Abstract

Carcinoma endometrium is the most common malignancy of the female genital tract in the developed world and the fourth most common cancer in women after breast, lung, and colorectum. The estimated new cases from endometrial cancer in the United States are 52,630 and deaths are 8,590 [1]. It is the second most common malignancy of the female genital tract in the developing world. The incidence in developing countries and Japan are four to five times lower than the developed world. In India, the rates are as low as 4.3 per 100,000 [2]. In recent years incidence in India is increasing – double the incidence as per recent cancer registry data. Due to increasing magnitude of the problem, screening and steps of prevention are of great importance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cancer facts & figures 2014: annual publication of the American Cancer Society. Atlanta

    Google Scholar 

  2. Balasubramaniam G, Sushama S, Rasika B, Mahantshetty U. Hospital-based study of endometrial cancer survival in Mumbai, India. Asian Pac J Cancer Prev. 2013;14(2):977–80.

    Article  PubMed  Google Scholar 

  3. Geldenhuys L, Murray ML. Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium. Acta Cytol. 2007;51(1):47–50.

    Article  PubMed  Google Scholar 

  4. Moatamed NA, Le LT, Levin MR, Govind R, Apple SK. In Papanicolaou smears, benign appearing endometrial cells bear no significance in predicting uterine endometrial adenocarcinomas. Diagn Cytopathol. 2013;41(4):335–41.

    Article  PubMed  Google Scholar 

  5. Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol. 2004;24(5):558–65.

    Article  CAS  PubMed  Google Scholar 

  6. Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998;280(17):1510–7.

    Article  CAS  PubMed  Google Scholar 

  7. Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA. 1997;277(11):915–9.

    Article  CAS  PubMed  Google Scholar 

  8. Berek JS, Hacker NF. Berek and Hacker’s gynecologic oncology. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2010. p. 396.

    Google Scholar 

  9. Fleischer AC, Wheeler JE, Lindsay I, Hendrix SL, Grabill S, Kravitz B, et al. An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. Am J Obstet Gynecol. 2001;184(2):70–5.

    Article  CAS  PubMed  Google Scholar 

  10. Saatli B, Yildirim N, Olgan S, Koyuncuoglu M, Emekci O, Saygılı U. The role of endometrial thickness for detecting endometrial pathologies in asymptomatic postmenopausal women. Aust N Z J Obstet Gynaecol. 2014;54(1):36–40.

    Article  PubMed  Google Scholar 

  11. Archer DF, McIntyre-Seltman K, Wilborn Jr WW, Dowling EA, Cone F, Creasy GW, et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol. 1991;165(2):317–20. discussion 320–2.

    Article  CAS  PubMed  Google Scholar 

  12. Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginalsonographic measurement of the endometrium as predictors of endometrial cancer. Am J Obstet Gynecol. 2003;188(2):401–8.

    Article  CAS  PubMed  Google Scholar 

  13. Fung MF, Reid A, Faught W, Le T, Chenier C, Verma S, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol. 2003;91(1):154–9.

    Article  CAS  PubMed  Google Scholar 

  14. American College of Obstetricians and Gynecologists. Tamoxifen and uterine cancer. Committee opinion no. 601. Obstet Gynecol. 2014;123:1394–7.

    Google Scholar 

  15. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.

    Article  CAS  PubMed  Google Scholar 

  16. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997;66:233–7.

    Article  CAS  PubMed  Google Scholar 

  17. Achiron R, Lipitz S, Sivan E, Goldenberg M, Horovitz A, Frenkel Y, et al. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Ultrasound Obstet Gynecol. 1995;6:116–20.

    Article  CAS  PubMed  Google Scholar 

  18. Bertelli G, Venturini M, Del Mastro L, Garrone O, Cosso M, Gustavino C, et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat. 1998;47:41–6.

    Article  CAS  PubMed  Google Scholar 

  19. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol. 1999;17:2050–4.

    CAS  PubMed  Google Scholar 

  20. Markovitch O, Tepper R, Aviram R, Fishman A, Shapira J, Cohen I. The value of sonohysterography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol. 2004;94:754–9.

    Article  CAS  PubMed  Google Scholar 

  21. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol. 1998;91:40–4.

    Article  CAS  PubMed  Google Scholar 

  22. Berliere M, Radikov G, Galant C, Piette P, Marbaix E, Donnez J. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer. 2000;36 suppl 4:S35–6.

    Article  PubMed  Google Scholar 

  23. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol. 2002;101:58–63.

    Article  CAS  PubMed  Google Scholar 

  24. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol. 2005;192:1230–7. discussion 1237–9.

    Article  PubMed  Google Scholar 

  25. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994;55(2):164–8.

    Article  CAS  PubMed  Google Scholar 

  26. Fornander T, Hellström AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst. 1993;85(22):1850–5.

    Article  CAS  PubMed  Google Scholar 

  27. Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol. 2000;18(20):3459–63.

    CAS  PubMed  Google Scholar 

  28. Berry E, Lindheim SR, Connor JP, Hartenbach EM, Schink JC, Harter J, Eickhoff JC, Kushner DM. Sonohysterography and endometrial cancer: incidence and functional viability of disseminated malignant cells. Am J Obstet Gynecol. 2008;199(3):240.e1–8.

    Article  Google Scholar 

  29. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, et al. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. BJOG. 2003;110(12):1099–106.

    Article  CAS  PubMed  Google Scholar 

  30. Bradley WH, Boente MP, Brooker D, Argenta PA, Downs LS, Judson PL, et al. Hysteroscopy and cytology in endometrial cancer. Obstet Gynecol. 2004;104(5 Pt 1):1030–3.

    Article  PubMed  Google Scholar 

  31. Gumus II, Keskin EA, Kiliç E, Aker A, Kafali H, Turhan NO. Diagnostic value of hysteroscopy and hysterosonography in endometrial abnormalities in asymptomatic postmenopausal women. Arch Gynecol Obstet. 2008;278(3):241–4.

    Article  PubMed  Google Scholar 

  32. Zhu HL, Liang XD, Wang JL, Cui H, Wei LH. Hysteroscopy and directed biopsy in the diagnosis of endometrial carcinoma. Chin Med J (Engl). 2010;123(24):3524–8.

    Google Scholar 

  33. ACOG Committee Opinion. Routine cancer screening. Number 185, September 1997 (replaces no. 128, October 1993). Committee on gynecologic practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1997;59(2):157–61.

    Google Scholar 

  34. Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH, et al. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 study). Am J Obstet Gynecol. 1997;176(2):377–80.

    Article  CAS  PubMed  Google Scholar 

  35. Watson P, Vasen HF, Mecklin JP, Järvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med. 1994;96(6):516–20.

    Article  CAS  PubMed  Google Scholar 

  36. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214–8.

    Article  CAS  PubMed  Google Scholar 

  37. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110(4):1020–7.

    Article  CAS  PubMed  Google Scholar 

  38. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6(1):105–10.

    Article  CAS  PubMed  Google Scholar 

  39. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107(2):159–62.

    Article  PubMed  Google Scholar 

  40. Boks DE, Trujillo AP, Voogd AC, Morreau H, Kenter GG, Vasen HF, et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer. 2002;102(2):198–200.

    Article  CAS  PubMed  Google Scholar 

  41. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424–5.

    Article  CAS  PubMed  Google Scholar 

  42. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2005. CA Cancer J Clin. 2005;55(1):31–44. quiz 55–6, 2005 Jan–Feb.

    Article  PubMed  Google Scholar 

  43. Helder-Woolderink JM, De Bock GH, Sijmons RH, Hollema H, Mourits MJ. The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome. Gynecol Oncol. 2013;131(2):304–8.

    Article  CAS  PubMed  Google Scholar 

  44. Critchley HO, Warner P, Lee AJ, Brechin S, Guise J, Graham B. Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status. Health Technol Assess. 2004;8(34):iii–iv. 1–139.

    Article  CAS  PubMed  Google Scholar 

  45. Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives–findings in a large cohort study. Br J Cancer. 1995;71(6):1340–2.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361(9364):1159–67.

    Article  PubMed  Google Scholar 

  47. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10(4):277–84.

    Article  CAS  PubMed  Google Scholar 

  48. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001;45(3 Suppl):S116–24.

    Article  CAS  PubMed  Google Scholar 

  49. Paxton RJ, King DW, Garcia-Prieto C, Connors SK, Hernandez M, Gor BJ, Jones LA. Associations between body size and serum estradiol and sex hormone-binding globulin levels in premenopausal African American women. J Clin Endocrinol Metab. 2013;98(3):E485–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Troisi R, Potischman N, Hoover RN, Siiteri P, Brinton LA. Insulin and endometrial cancer. Am J Epidemiol. 1997;146(6):476–82.

    Article  CAS  PubMed  Google Scholar 

  51. Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers: the Iowa Women’s Health Study. Int J Obes Relat Metab Disord. 2003;27(12):1447–52.

    Article  CAS  PubMed  Google Scholar 

  52. Du M, Kraft P, Eliassen AH, Giovannucci E, Hankinson SE, De Vivo I. Physical activity and risk of endometrial adenocarcinoma in the Nurses’ Health Study. Int J Cancer. 2014;134(11):2707–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Keum N, Ju W, Lee DH, Ding EL, Hsieh CC, Goodman JE, et al. Leisure-time physical activity and endometrial cancer risk: doses response meta-analysis of epidemiological studies. Int J Cancer. 2014;135(3):682–94.

    Article  CAS  PubMed  Google Scholar 

  54. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst. 2004;96(21):1635–8.

    Article  PubMed  Google Scholar 

  55. Littman AJ, Voigt LF, Beresford SA, Weiss NS. Recreational physical activity and endometrial cancer risk. Am J Epidemiol. 2001;154(10):924–33.

    Article  CAS  PubMed  Google Scholar 

  56. Colbert LH, Lacey Jr JV, Schairer C, Albert P, Schatzkin A, Albanes D. Physical activity and risk of endometrial cancer in a prospective cohort study (United States). Cancer Causes Control. 2003;14(6):559–67.

    Article  PubMed  Google Scholar 

  57. McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer. 2008;8(3):205–11.

    Article  CAS  PubMed  Google Scholar 

  58. Laughlin GA, Ix JH, Cummins K, Allison MA, Daniels LB. Extremes of an aromatase index predict increased 25-year risk of cardiovascular mortality in older women. Clin Endocrinol (Oxf). 2012;77(3):391–8.

    Article  CAS  Google Scholar 

  59. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.

    Article  CAS  PubMed  Google Scholar 

  60. Pike MC, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and ovary. Oncogene. 2004;23:6379–91.

    Article  CAS  PubMed  Google Scholar 

  61. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Salmeron-Castro J, Hernandez-Avila M. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res. 1999;59(15):3658–62.

    CAS  PubMed  Google Scholar 

  62. Berek JS. Berek and Novak’s gynecology. 14th ed. Philadelphia: Lippincott Williams and Willkins; 2007. p. 466.

    Google Scholar 

  63. Lacey JV, Jr Ioffe OB, Ronnett BM, Rush BB, Richesson DA, Chatterjee N. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer. 2008;98(1):45–53.

    Article  PubMed Central  PubMed  Google Scholar 

  64. Berek JS. Berek and Novak’s gynecology. 14th ed. Philadelphia: Lippincott Williams and Willkins; 2007. p. 1348.

    Google Scholar 

  65. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;8, CD000402.

    PubMed  Google Scholar 

  66. Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol. 2014;142:83–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. International Agency for Research on Cancer: IARC Handbooks of Cancer Prevention. Volume 8: fruit and vegetables. Lyon: International Agency for Research on Cancer; 2003.

    Google Scholar 

  68. Bandera EV, Kushi LH, Gifkins DM, et al. WCRF systematic literature review: the association between food, nutrition, and physical activity and the risk of endometrial cancer and underlying mechanisms. Washington, DC: World Cancer Research Fund, American Institute for Cancer Research; 2006.

    Google Scholar 

  69. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003;95(15):1158–64.

    Article  CAS  PubMed  Google Scholar 

  70. Xu WH, Zheng W, Xiang YB, Ruan ZX, Cheng JR, Dai Q, et al. Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case–control study. BMJ. 2004;328(7451):1285.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Zeleniuch-Jacquotte A, Gallicchio L, Hartmuller V, Helzlsouer KJ, McCullough ML, Setiawan VW, et al. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172(1):36–46.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Neuhouser ML, Wassertheil-Smoller S, Thomson C, Aragaki A, Anderson GL, Manson JE, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women’s Health Initiative cohorts. Arch Intern Med. 2009;169(3):294–304.

    Article  PubMed  Google Scholar 

  73. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, et al. American Cancer Society 2010 nutrition and physical activity guidelines advisory. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62(1):30–67.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical and Gynaecologic Oncology, Welcare Hospital, Kochi, Kerala, India

    T. J. Simi Raj MD, DGO

  2. Department of Surgical and Gynecologic Oncology, Welcare Hospital and Lakeshore Hospital and Research Centre, Kochi, Kerala, India

    K. Chitrathara MD(Gynec), M.Ch(Uro), FAIS

Authors
  1. T. J. Simi Raj MD, DGO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Chitrathara MD(Gynec), M.Ch(Uro), FAIS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. J. Simi Raj MD, DGO .

Editor information

Editors and Affiliations

  1. Obstetrics and Gynecology, University College of Medical Sciences, New Delhi, India

    Shalini Rajaram

  2. Surgical &Gynec Oncology, Lakeshore & Welcare Hospitals, Kochi, Kerala, India

    Chitrathara K

  3. Gynec Onclogy, Tata Memorial Hospital, Mumbai, India

    Amita Maheshwari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer India

About this chapter

Cite this chapter

Simi Raj, T.J., Chitrathara, K. (2015). Screening and Prevention of Carcinoma Endometrium. In: Rajaram, S., K, C., Maheshwari, A. (eds) Uterine Cancer. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1892-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-1892-0_4

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-1891-3

  • Online ISBN: 978-81-322-1892-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation